China Peptide CDMO Support for Overseas B2B Projects

Direct answer

A China peptide CDMO discussion should begin with a defined molecule, project stage, required deliverables and decision criteria. The buyer should provide the available sequence or structural information, target material form, quantity, specification expectations, analytical requirements, packaging, destination and schedule. The CDMO team can then clarify which activities are within scope, which information is still missing and how development or supply milestones will be reviewed.

The value of a CDMO project is not demonstrated by a long list of generic capabilities. It is demonstrated by a traceable path from technical input to an agreed process, analytical package, batch documentation and delivered material. Qualified overseas B2B buyers should therefore evaluate project definition, communication, change control and evidence at each stage.

Define the project before comparing providers

Peptide projects can begin from very different starting points. One buyer may need an early feasibility discussion, another may have an existing process to transfer, and another may need scale-up or recurring batch coordination. Before requesting a proposal, define:

• the peptide name, sequence or available structural description;
• the present development or procurement stage;
• the requested quantity and possible later scale;
• the target purity, material form and other specification requirements;
• known modifications, conjugations or sequence-related concerns;
• analytical records and document deliverables required for review;
• packaging, storage, transport and destination requirements;
• the requested timeline and the event that determines project completion.

This information allows both parties to separate confirmed scope from assumptions. It also prevents an early estimate from being treated as a final technical or commercial commitment.

Peptide CDMO project workstream matrix

The exact workstreams depend on the molecule and project. The following matrix provides a practical structure for defining responsibilities and review evidence.

Workstream	Buyer input	Project output to define	Review evidence
Project and molecule definition	Sequence or structure, intended B2B project stage, quantity and target attributes	Confirmed identity, assumptions, exclusions and information gaps	Written scope and responsibility list
Technical transfer or feasibility	Available process, analytical and historical information	Transfer plan or feasibility questions, material needs and initial risks	Input inventory, gap assessment and agreed next step
Process development	Target specification, known process constraints and scale objective	Development experiments, process choices and defined decision points	Development summary, process observations and relevant analytical comparisons
Analytical scope	Required attributes, methods or buyer-specific reporting needs	Agreed tests, method responsibilities, reporting format and sample plan	Specification, analytical reports and traceable sample or batch references
Scale-up and batch execution	Required quantity, schedule and acceptable change boundaries	Scale-up plan, batch assumptions, in-process observations and output	Batch-specific records, yield basis and quality comparison
Purification and final isolation	Purity target, material form and relevant impurity concerns	Purification approach, fraction criteria, recovery and final isolation conditions	Chromatographic profile, impurity reporting and final test results
Quality documentation	Documents needed for the buyer's current review stage	Confirmed document list, format, confidentiality and delivery timing	COA, specification and applicable analytical, storage or packaging information
Packaging and delivery	Quantity split, container, label, storage, destination and transport needs	Packaging configuration and shipment coordination plan	Label, batch link, packing information and shipment confirmation
Change and issue communication	Buyer approval roles and material change criteria	Contacts, escalation path, response timing and change-notification scope	Decision log, updated scope and written resolution

Technical transfer and feasibility assessment

When a buyer has an existing process or analytical package, technical transfer should start with an inventory of available information. This may include sequence and modification details, process description, material specifications, analytical methods, historical results, known impurities, handling requirements and previous scale experience.

The receiving team should identify information gaps and assumptions before execution. A transfer cannot be evaluated only by reproducing a final purity value. The parties need to understand whether materials, equipment configuration, methods, reporting conventions and final isolation conditions are comparable.

For a new molecule or an early project, feasibility work should define the limited question being answered. Examples include whether the sequence can be assembled under the proposed strategy, whether a modification can be introduced selectively, whether the crude profile supports purification development, or whether the requested final form can be prepared and handled.

Process-development scope

Process development should connect experiments to a specific decision. For an SPPS-based peptide, relevant questions can involve resin and loading, difficult coupling regions, deprotection, sequence aggregation, cleavage, crude isolation, product-specific modification, purification and final drying. Other synthesis strategies may require a different set of controls.

Not every project requires complete optimization of every step. The buyer and CDMO should agree which parameters will be explored, which outcomes define progression and what evidence will be reported. A development summary should distinguish observations from confirmed process limits and should identify unresolved risks that remain for later scale-up.

Analytical requirements and document ownership

Analytical scope should be agreed before samples or batches are evaluated. The product specification defines the required attributes and acceptance criteria. The COA summarizes batch results. HPLC, identity or mass information, impurity data and other records provide supporting evidence where applicable.

The project plan should state:

• which tests are required at each stage;
• which party provides or performs each method;
• which method version and reporting units apply;
• how samples and results are linked to the project or batch;
• how atypical, out-of-specification or unclear results are communicated;
• which raw data, reports or summaries are included in the deliverables;
• how method or specification changes are approved.

Document names alone do not establish regulatory suitability. The buyer should define the evidence required for the current project and independently determine jurisdiction-specific registration and import requirements.

Scale-up and batch comparability

Scale-up can change mixing, heat and mass transfer, addition time, filtration, hold time, purification loading, fraction selection, concentration and drying behavior. A scale-up review should therefore compare both process observations and quality output.

Useful comparison points include material inputs, process scale, defined parameters, in-process observations, crude profile, purification recovery, final yield basis, specification, analytical-method revision and final results. If methods or reporting conventions change, that difference should be documented before numerical results are interpreted as a process trend.

The parties should also define whether the goal is a development batch, a sample, a scale demonstration or recurring supply. These outputs have different evidence and scheduling requirements.

Packaging, storage and international delivery planning

The final delivery plan should be part of the technical scope rather than an afterthought. Confirm the material form, total quantity, aliquot or container configuration, label content, batch identification, storage temperature, protective packaging, destination and requested transport conditions.

Storage guidance must apply to the supplied form. Conditions for a prepared solution should not be substituted for the unopened material. For international delivery, the buyer is responsible for confirming local import eligibility and providing accurate destination and consignee information.

Communication and change control

Overseas projects benefit from a written communication structure. Identify the commercial contact, technical contact, quality-document contact and buyer approver where appropriate. Define how questions, data and revisions will be exchanged and how urgent issues will be escalated.

A simple decision log can record the question, evidence reviewed, decision, owner and date. Changes affecting product identity, specification, method, process assumptions, material form, packaging, storage, timeline or document scope should be communicated before they alter the agreed deliverable.

What a qualified peptide CDMO inquiry should include

To begin a useful discussion, provide:

• company type and responsible team;
• peptide name, sequence or available structural information;
• modification, conjugation or material-form requirements;
• current project stage and required workstream;
• requested quantity and potential later scale;
• target purity, specification or key analytical attributes;
• available process and analytical information for transfer, if any;
• required documents and review format;
• packaging, storage, destination and schedule;
• confidentiality or communication requirements.

Project feasibility, scope, documentation and supply suitability are confirmed case by case. No article can confirm regulatory acceptance, manufacturing certification or project capability for an unspecified molecule. Services are for qualified B2B projects only and not for personal use or direct consumer sale.

FAQ

What information is needed to start a peptide CDMO discussion?

Provide the peptide identity or sequence, modifications, project stage, quantity, target attributes, analytical and document requirements, packaging, destination and timeline.

What is the difference between technical transfer and process development?

Technical transfer begins from an existing process or data package and assesses how it can be reproduced or adapted. Process development generates or improves process knowledge to meet defined project objectives.

Does every peptide CDMO project require full process development?

No. The required work depends on the starting information, molecule, scale, specification and intended deliverable.

Which analytical documents can be included?

The scope may include a specification, COA and applicable HPLC, identity, impurity, storage or packaging information. Exact availability and format are confirmed for the project.

How should scale-up success be evaluated?

Use agreed process observations, crude and purified profiles, recovery, yield basis, final quality attributes and comparable analytical methods rather than batch size alone.

When should packaging and transport be discussed?

They should be defined during project scoping and confirmed before batch execution or shipment, especially when temperature, aliquoting or destination requirements apply.

Can regulatory files or certifications be assumed from CDMO support?

No. Their relevance and availability depend on the actual entity, manufacturing arrangement, product and jurisdiction and require current supporting evidence.

Who is responsible for import and local regulatory compliance?

The buyer is responsible for confirming local registration, import and regulatory requirements in the destination jurisdiction.

Related resources

• Peptide supply and project capabilities
• Peptide API product portfolio
• Quality documentation
• SPPS technical barriers in GLP-1 peptide API development
• Submit a qualified B2B project inquiry